Yoshinobu (Yoshi) Konishi
@Yoshi_konnykid
Followers
45
Following
112
Media
0
Statuses
130
Physician-scientist, instructor @harvardmed @DanaFarber, Multiple Myeloma @LabGhobrial.
Brookline, MA
Joined December 2011
Just out in the New England Journal of Medicine! Our comprehensive Review on MGUS: Monoclonal Gammopathy of Undetermined Significance @NEJM
https://t.co/vu9REOKBPS 5% of people over age 50 have MGUS. Every physician needs to know and understand MGUS. Lots of Tables and
21
261
888
Grateful to share my promotion to Associate Professor! Thanks to mentors who guided me, mentees who inspire me, colleagues, collaborators, admins, friends, family and myself ✨for believing in the journey. 🙏
187
102
4K
If you don't get why Trump bombed Iran's nuclear facilities, or are concerned he did it for Israel, this will help.
Seeing a lot of takes saying Trump is simply defending Israel, or has been manipulated by Netanyahu. There is clear America-first rationale for the bombing, even if you ignore Israel entirely. And it’s important to understand it, even if you disagree: 1. Iran had enriched
361
2K
8K
Participants at an NCI Division of Cancer Biology workshop share "Ten Challenges and Opportunities in Computational #ImmunoOncology" and discuss how computational strategies inform the development of effective #immunotherapies. https://t.co/WSTkjFMaFp
1
30
61
Looking for reviewers before Christmas https://t.co/EOnJDgOgpg
20
269
2K
Sorry I accidentally left out Belantamab, which is active and likely to be approved again soon. My fault. Revised Figure. #ASH24
0
7
34
Kudos to @IrenemGhobrial @LabGhobrial for the amazing work presented at #ASH24 Always pushing technology to the next level and bringing new insight in myeloma #mmsm My favorite: the use of imaging mass cytometry to understand CRS, hematotoxicity and survival after CAR T therapy
2
9
25
2
7
35
Check out our new study in @NatureMedicine looking at nonrelapse mortality after CAR-T cell treatment with Tobias Tix and @KRejeski
https://t.co/36tDpkwg3S
5
12
53
Getting MRD as an endpoint was a great partnership between academia and industry and patient organization. A model to follow. Patients are three winner. @VincentRK #@NoopurRajeMD #myelomasociety
10
24
100
How to write a review simple enough to elucidate MM CAR-T for students/early-career HCWs while satisfactorily providing the latest updates on the field for Hem/Onc peeps? Well, it’s not easy… But me and @mdnorahsadek tried: https://t.co/sOcuKnLRW4 Check out our state-of-the-art
2
10
40
I once saw someone refer to their PBMC ficoll process taking 2.5 hrs so I want to put our lab's SOP out there. Saves tonnes of ⏱ without compromising quality 👌 Just pop and drop those pipettes of ficoll 😎
37
115
854
It’s the proliferation, s—— Spatial predictors of immunotherapy response in triple-negative breast cancer | Nature
nature.com
Nature - Imaging mass cytometry is used to map the multicellular dynamics of immune checkpoint blockade-treated triple-negative breast cancer, finding that key proliferative fractions and...
1
39
149
ハーバード大学が75年にわたり研究し続けている「人は何が幸せか」について。金・富・健康ではなく、「同じ志をもつコミュニティで頼り頼られ生きること」と結論づけた。
153
22K
132K
A big thank you to the #JapaneseSocietyofHematology & Dr. Chiba for hosting an excellent scientific symposium in Tsukuba. An incredible three days of science, culture & food!
0
1
24
Practical guidelines and recommendations for infection prophylaxis with CAR T and bispecific antibodies in #MultipleMyeloma from the COMMIT Consortium https://t.co/YeaQVzLuxn
@MeeraMohanMD @End_myeloma @rajshekharucms @SusanBal9 @nsc_natalie @BerdejaJesus #mmsm
0
33
74
Excited to share a new preprint from @TCupedo lab where we used #scRNAseq and functional studies to investigate the composition and function of the bone marrow #NKcell compartment in #myeloma at diagnosis, during treatment, and at relapse. https://t.co/m7PDX8f1Nz
5
21
64
Blood Cancer Discovery's very first Impact Factor is released today. Huge thanks to our authors, reviewers, readers, academic board, Editors-In-Chief, in-house team of @BCD_AACR and our sister journals for reaching this mark!
19
14
137